Authors: Ring, BJ Eckstein, JA Gillespie, JS Binkley, SN Vandenbranden, M Wrighton, SA

Citation: Bj. Ring et al., Identification of the human cytochromes P450 responsible for in vitro formation of R- and S-norfluoxetine, J PHARM EXP, 297(3), 2001, pp. 1044-1050

Authors: Ekins, S Bravi, G Binkley, S Gillespie, JS Ring, BJ Wikel, JH Wrighton, SA

Citation: S. Ekins et al., Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors, DRUG META D, 28(8), 2000, pp. 994-1002

Authors: Ekins, S Bravi, G Binkley, S Gillespie, JS Ring, BJ Wikel, JH Wrighton, SA

Citation: S. Ekins et al., Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors, PHARMACOGEN, 9(4), 1999, pp. 477-489

Authors: Dantzig, AH Shepard, RL Law, KL Tabas, L Pratt, S Gillespie, JS Binkley, SN Kuhfeld, MT Starling, JJ Wrighton, SA

Citation: Ah. Dantzig et al., Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities, J PHARM EXP, 290(2), 1999, pp. 854-862

Authors: Ekins, S Bravi, G Binkley, S Gillespie, JS Ring, BJ Wikel, JH Wrighton, SA

Citation: S. Ekins et al., Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors, J PHARM EXP, 290(1), 1999, pp. 429-438

Authors: Ekins, S Bravi, G Ring, BJ Gillespie, TA Gillespie, JS Vandenbranden, M Wrighton, SA Wikel, JH

Citation: S. Ekins et al., Three-dimensional quantitative structure activity relationship analyses ofsubstrates for CYP2B6, J PHARM EXP, 288(1), 1999, pp. 21-29